Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.47%
1,067.36
+4.96
+0.47%
—1,062.401,064.141,071.991,061.02——
SIXC
Communications
SIXC
Communications
SIXC
-0.54%
603.48
-3.26
-0.54%
—606.74606.74609.84602.33——
SIXE
Energy
SIXE
Energy
SIXE
+0.54%
1,244.93
+6.72
+0.54%
—1,238.211,236.601,247.741,232.10——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.68%
1,730.38
+11.77
+0.68%
—1,718.611,723.231,741.481,717.47——
SIXM
Financials
SIXM
Financials
SIXM
+0.33%
639.47
+2.10
+0.33%
—637.37638.27642.30638.27——
SIXR
Staples
SIXR
Staples
SIXR
+0.16%
854.95
+1.36
+0.16%
—853.59854.05858.19851.34——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.11%
218.56
+0.23
+0.11%
—218.33218.33219.73217.15——
SIXT
Technology
SIXT
Technology
SIXT
+1.02%
3,631.59
+36.78
+1.02%
—3,594.813,620.103,657.473,615.34——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.80%
915.77
+7.23
+0.80%
—908.54909.50917.35907.07——
SIXV
Health care
SIXV
Health care
SIXV
+1.19%
1,512.81
+17.81
+1.19%
—1,495.001,499.611,517.101,499.61——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.41%
2,408.21
+9.90
+0.41%
—2,398.312,406.822,421.802,404.22——
CVM:NYSEAMERICAN
CEL-SCI Corp
$1.42
-2.07%
(-0.030) 1D
$1.46
+2.71% (+0.039)
After hours
Closed: May 22, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CVM...
Open
$1.45
High
$1.48
Low
$1.37
Mkt. cap
20.58M
Avg. vol.
615.82K
Volume
276.96K
52-wk high
$13.48
52-wk low
$0.89
EPS
-$5.24
Beta
0.70
Shares outstanding
8.49M
No. of employees
43
News stories
From sources across the web
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
FoundedMar 1983
HeadquartersVienna, Virginia, United States
SectorBiotechnology
Websitecel-sci.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
3.74M
3.70M
3.68M
-
Cost of revenue
3.74M
3.70M
3.68M
-
Research and development expenses
-
-
-
3.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.75M
2.33M
1.69M
1.56M
Operating expense
1.75M
2.33M
1.69M
5.33M
Total operating expenses
5.49M
6.03M
5.37M
5.33M
Operating income
-5.49M
-6.03M
-5.37M
-5.33M
Other non operating income
-3.77K
60.94K
-
-22.26K
EBT including unusual items
-5.66M
-6.10M
-5.47M
-5.47M
EBT excluding unusual items
-5.66M
-6.10M
-5.46M
-5.47M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-5.66M
-6.10M
-5.47M
-5.47M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-172.05K
-128.50K
-87.79K
-117.48K
Net interest expenses
-172.05K
-128.50K
-87.79K
-117.48K
Depreciation and amortization charges
-
-
-
-
EBITDA
-4.53M
-5.51M
-4.40M
-4.37M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer